Literature DB >> 9609417

Sequential production of leukaemia inhibitory factor by blood cell culture in patients with ARDS.

D Gruson1, G Hilbert, M Juzan, J L Taupin, V Coulon, J F Moreau, N Gualde, G Gbikpi-Benissan.   

Abstract

OBJECTIVE: Leukaemia inhibitory factor (LIF) is a polyfunctional cytokine integrated in cytokine networks and its concentration has been shown to be elevated in bronchoalveolar lavage fluid of patients with the acute respiratory distress syndrome (ARDS). The aim of our study was to evaluate the production of LIF by culturing blood cells from patients with ARDS. PATIENTS: 8 patients with ARDS, 8 patients with pneumonia and 5 healthy subjects. MEASUREMENTS AND
RESULTS: The blood samples were taken on day 1 after onset of ARDS. LIF was measured, in the cell-free supernatant, with an enzyme-linked immunosorbent assay after 24 h, 48 h and 72 h of blood cell culture. LIF was detectable in some patients in the ARDS group: at i) at 24 h and 48 h: in 2 patients ii) at 72 h in 4/5 patients (140 +/- 231 pg/ml). Only in the 4 patients in whom LIF was measured at 72 h was ARDS associated with the multiple organ dysfunction syndrome. Furthermore, among the 5 patients with ARDS who subsequently died, 4 had a detectable LIF.
CONCLUSIONS: We have observed that LIF was produced only in ARDS, but not in all patients. The production of LIF seems to be a good indicator of the severity of ARDS. These preliminary results must be confirmed by a larger study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9609417     DOI: 10.1007/s001340050582

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  High levels of leukaemia inhibitory factor in ARDS.

Authors:  P G Jorens; R De Jongh; L L Bossaert; W De Backer; A G Herman; H Pollet; E Bosmans; J L Taupin; J F Moreau
Journal:  Cytokine       Date:  1996-11       Impact factor: 3.861

Review 2.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

Review 3.  Biological markers of acute lung injury: prognostic and pathogenetic significance.

Authors:  J F Pittet; R C Mackersie; T R Martin; M A Matthay
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

4.  An expanded definition of the adult respiratory distress syndrome.

Authors:  J F Murray; M A Matthay; J M Luce; M R Flick
Journal:  Am Rev Respir Dis       Date:  1988-09

5.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

6.  Production of human interleukin for DA cells (HILDA)/leukemia inhibitory factor (LIF) by activated monocytes.

Authors:  I Anegon; J F Moreau; A Godard; Y Jacques; M A Peyrat; M M Hallet; G Wong; J P Soulillou
Journal:  Cell Immunol       Date:  1990-10-01       Impact factor: 4.868

7.  A monoclonal antibody based elisa for quantitation of human leukaemia inhibitory factor.

Authors:  J L Taupin; N Gualde; J F Moreau
Journal:  Cytokine       Date:  1997-02       Impact factor: 3.861

8.  One-year enzyme-linked immunosorbent assay follow-up of human interleukin for Da cells/leukemia inhibitory factor in blood and urine of 22 kidney transplant recipients.

Authors:  D Morel; J L Taupin; C Combe; L Potaux; N Gualde; J F Moreau
Journal:  Transplantation       Date:  1994-12-15       Impact factor: 4.939

9.  Induction of cytokine expression by leukemia inhibitory factor.

Authors:  P M Villiger; Y Geng; M Lotz
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids.

Authors:  P Waring; K Wycherley; D Cary; N Nicola; D Metcalf
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.